Pathophysiology of Parkinson's disease

International Review of Psychiatry

Volumn 12, Issue 4, 2000, Pages 270-280

  Mandir, A S ^a   Vaughan, C ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; NEUROTOXIN; UBIQUITIN;

ARTICLE; BASAL GANGLION; COGNITION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOPAMINERGIC NERVE CELL; GENE MUTATION; LEWY BODY; MOTOR CORTEX; NERVE DEGENERATION; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

EID: 0033635705     PISSN: 09540261     EISSN: None     Source Type: Journal    
DOI: 10.1080/09540260020002497     Document Type: Article

References (126)

1. Frequency of dementia in Parkinson disease
2. Range of neuropsychiatric disturbances in patients with Parkinson's disease
3. Levodopa in the treatment of Parkinson's disease: A consensus meeting
4. Parkinson's disease and depression: Evidence for an alteration of the basal limbic system detected by transcranial sonography
5. Pallidal stimulation for Parkinson's disease. Two targets?
6. Transient acute depression induced by high-frequency deep-brain stimulation
7. Physiology of MPTP tremor
8. Kinetics of nigral degeneration in a chronic model of MPTP-treated mice
9. Modulation of levodopa-induced motor response complications by NMDA antagonists in Parkinson's disease
10. Wearing-off fluctuations in Parkinson's disease: Contribution of postsynaptic mechanisms
11. Internal versus external cues and the control of attention in Parkinson's disease
12. Parkinson's disease and dementia: Norepinephrine and dopamine in locus ceruleus
13. Neostriatal mechanisms in Parkinson's disease
14. Parkinson's disease impairs the ability to change set quickly
15. Depression and Parkinson's disease: A review
16. Behavioral and psychiatric symptoms associated with Huntington's disease
17. Depression in patients with Parkinson's disease
18. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease
19. Primate models of movement disorders of basal ganglia origin
20. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease
21. MPTP primate model of Parkinson's disease: A mechanographic and electromyographic study
22. Cognitive and behavioral changes in patients with focal lesions of the basal ganglia
23. Regional metabolic correlates of surgical outcome following unilateral pallidotomy for Parkinson's disease
24. Executive function in Parkinson's disease and subcortical disorders
25. MPTP-induced parkinsonism: Relative changes in dopamine concentration in subregions of substantia nigra, ventral tegmental area and retrorubral field of symptomatic and asymptomatic vervet monkeys
26. Parkinson's disease: Neurodegenerative mechanisms and neuroprotective interventions - Report of a workshop
27. Ageing and Parkinson's disease: Substantia nigra regional selectivity
28. Cognitive outcomes after deep brain stimulation for Parkinson's disease: A review of initial studies and recommendations for future research
29. Abnormal influences of passive limb movement on the activity of globus pallidus neurons in parkinsonian monkeys
30. Neuropathology of Parkinson's disease
31. Similarities and differences between MPTP-induced parkinsonsim and Parkinson's disease. Neuropathologic considerations
32. Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys
33. Animal models of Parkinson's disease: An empirical comparison with the phenomenology of the disease in man
34. Risk factors for dementia, depression and psychosis in long-standing Parkinson's disease
35. Relationship of lesion location to clinical outcome following microelectrode-guided pallidotomy for Parkinson's disease
36. A physiological mechanism of bradykinesia
37. MPTP toxicity and the 'biochemical' blood-brain barrier
38. Parkinson's disease: From brain homogenate to treatment
39. Biochemical aspects of Parkinson's disease
40. Set-shifting aptitude in Parkinson's disease: External versus internal cues
41. A specific shifting deficit in Parkinson's disease: A reversal shift of consistent stimulus-response mappings
42. Precued shifting of attention between cognitive sets in Parkinson patients
43. Neurocognitive correlates of stereotactic thalamotomy and thalamic stimulation in Parkinsonian patients
44. A 10-year study of the incidence of and factors predicting dementia in Parkinson's disease
45. Identification and characterization of neurons with tremor-frequency activity in human globus pallidus
46. The evolution of nigrostriatal neurochemical changes in the MPTP-treated squirrel monkey
47. Uptake of MPP(+) by dopamine neurons explains selectivity of parkinsonism-inducing neurotoxin. MPTP
48. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: Characterization and localization of receptor binding sites in rat and human brain
49. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: Uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity
50. Oxidative mechanisms in nigral cell death in Parkinson's disease
51. Participation of brain monoamine oxidase B form in the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: Relationship between the enzyme inhibition and the neurotoxicity
52. Electrophysiologic detection of extrapyramidal motor signs in Alzheimer's disease
53. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
54. Mice deficient in cellular glutathione peroxidase show increased vulnerability to malonate, 3-nitropropionic acid, and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine
55. AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys
56. Opposite motor effects of pallidal stimulation in Parkinson's disease
57. Elevated levels of harman and norharman in cerebrospinal fluid of parkinsonian patients
58. Lewy bodies are ubiquitinated. A light and electron microscopic immunocytochemical study
59. L-dopa withdrawal in Parkinson's disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunction
60. The etiology of Parkinson's disease with emphasis on the MPTP story
61. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure
62. Pesticides and Parkinson's disease
63. Cognitive impairments in Parkinson's disease
64. Apathy is not depression
65. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease
66. Changes in cerebral activity pattern due to subthalamic nucleus or internal pallidum stimulation in Parkinson's disease
67. Neuropsychiatric assessment of patients with hyperkinetic and hypokinetic movement disorders
68. Distribution of choline acetyltransferase and glutamate decarboxylase within the substantia nigra and in other brain regions from control and Parkinsonian patients
69. Relationship of lesion location to cognitive outcome following microelectrode-guided pallidotomy for Parkinson's disease: Support for the existence of cognitive circuits in the human pallidum
70. Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism
71. Neuropsychiatric aspects of Parkinson's disease
72. Depression in Parkinson's disease: A biochemical and organic viewpoint
73. Pathophysiology of motor response complications in Parkinson's disease: Hypotheses on the why, where, and what
74. Parkinsonian symptomatology. An anatomical and physiological analysis
75. Neurotoxicity of endogenous cysteinylcatechols
76. Regional biotransformation of MPTP in the CNS of rodents and its relation to neurotoxicity
77. Abnormal basal ganglia outflow in Parkinson's disease identified with PET. Implications for higher cortical functions
78. MPTP-induced parkinsonism in primates: Pattern of striatal dopamine loss following acute and chronic administration
79. The neurotoxin MPTP does not reproduce in the rhesus monkey the interregional pattern of striatal dopamine loss typical of human idiopathic Parkinson's disease
80. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease
81. Movement-related potential measures of different modes of movement selection in Parkinson's disease
82. Motor cortex activation in Parkinson's disease: Dissociation of electrocortical and peripheral measures of response generation
83. Role of neuronal nitric oxide in 1-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity
84. Astrocytes convert the parkinsonism inducing neurotoxin, MPTP, to its active metabolite, MPP+
85. Set-shifting and spatial orientation in patients with Parkinson's disease
86. Neuronal synchronization of tonically active neurons in the striatum of normal and parkinsonian primates
87. Time course of nigrostriatal degeneration in parkinson's disease. A detailed study of influential factors in human brain amine analysis
88. Cognitive impairment and the brain dopaminergic system in Parkinson disease: [18F]fluorodopa positron emission tomographic study
89. Parkinson's disease mortality and pesticide exposure in California 1984-1994
90. Motor set in Parkinson's disease
91. The subthalamic nucleus and tremor in Parkinson's disease
92. Pallidotomy in Parkinson's disease increases supplementary motor area and prefrontal activation during performance of volitional movements an H2(15)O PET study
93. Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease
94. Mitochondrial complex I deficiency in Parkinson's disease
95. Mitochondrial involvement in Parkinson's disease, Huntington's disease, hereditary spastic paraplegia and Friedreich's ataxia
96. Mitochondrial complex I deficiency in Parkinson's disease
97. Mitochondrial complex I deficiency in Parkinson's disease
98. Anxiety disorders in Parkinson's disease: Insights into the neurobiology of neurosis
99. Cognitive deficits precede motor deficits in a slowly progressing model of parkinsonism in the monkey
100. Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice
101. Neuropsychological, neurological and functional outcome following pallidotomy for Parkinson's disease. A consecutive series of eight simultaneous bilateral and twelve unilateral procedures
102. Anxiety disorders and depressive disorders preceding Parkinson's disease: A case-control study
103. Glutathione-related enzymes in brain in Parkinson's disease
104. Readiness potential of cortical area 6 preceding self paced movement in Parkinson's disease
105. Functional and neuroanatomic correlations in poststroke depression: The Sunnybrook Stroke Study
106. L-dopa increases nigral production of hydroxyl radicals in vivo: Potential L-dopa toxicity?
107. Pattern of dopaminergic loss in the striatum of humans with MPTP induced parkinsonism
108. MPTP: A neurotoxin relevant to the pathophysiology of Parkinson's disease. The 1985 George C. Cotzias lecture
109. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies
110. Exposure to home pesticides linked to Parkinson disease
111. Cognitive change following MPTP exposure
112. Abnormal accumulation of NACP/alpha-synuclein in neurodegenerative disorders
113. Post-stroke depression
114. Neuropsychological consequences of posteroventral pallidotomy for the treatment of Parkinson's disease
115. Neuropsychological outcome of GPi pallidotomy and GPi or STN deep brain stimulation in Parkinson's disease
116. Unilateral pallidal stimulation for Parkinson's disease: Neurobehavioral functioning before and 3 months after electrode implantation
117. MPTP produces a pattern of nigrostriatal degeneration which coincides with the mosaic organization of the caudate nucleus
118. Chronic MPTP treatment reproduces in baboons the differential vulnerability of mesencephalic dopaminergic neurons observed in Parkinson's disease
119. NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease
120. The role of motor cortex in the pathophysiology of voluntary movement deficits associated with parkinsonism
121. Intrastriatal cografts of autologous adrenal medulla and sural nerve in MPTP-induced parkinsonian macaques: Behavioral and anatomical assessment
122. Electrophysiologic analysis of early Parkinson's disease
123. Preliminary report on adrenal medullary grafting and cografting with sural nerve in the treatment of hemiparkinson monkeys
124. Vulnerability to pesticide neurotoxicity is a lifetime issue
125. Models of basal ganglia function and pathophysiology of movement disorders